CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights
Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Marina Konopleva(The University of Texas MD Anderson Cancer Center), Andrew Garton(Cellecta (United States)), Nitin Jain(The University of Texas MD Anderson Cancer Center), Rossana Kazemimood(University of Rochester Medical Center), Julianne Smith(Albany Medical Center Hospital), Mónica L. Guzmán(Cornell University), Tianyu Cai(Southwest University of Science and Technology), R. Eric Davis(National Institutes of Health), Nathaniel R. Wilson(The University of Texas Health Science Center at Houston), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Jayastu Senapati(The University of Texas MD Anderson Cancer Center), Joseph D. Khoury(St. Jude Children's Research Hospital), Minas P. Economides(NYU Langone Health), Mayumi Sugita(Cornell University), Mark G. Frattini(Presbyterian Hospital), Gail J. Roboz(Cornell University)
Cited by 18
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k